Citations

Clear

4802 citation(s) found for "Yu, Jennifer".

Self‐report screening instruments differentiate bipolar disorder and borderline personality disorder
Palmer, Brian A. , Pahwa, Mehak , Geske, Jennifer R. , Kung, Simon , Nassan, Malik , Schak, Kathryn M. , Frye, Mark A. , Singh, Balwinder , Alarcón, Renato D. , Singh, Balwinder , Geske, Jennifer

Mayo Clinic

Brain and Behavior | May 31, 2021 | Volume: 11 | Issue: 7 | Pages: No page available

10.1002/brb3.2201 | PMID 34056864 Get It

AbstractBackgroundBipolar disorder (BD) and borderline personality disorder (BPD) share overlapping phenomenology and are frequently misdiagnosed. This study investigated the diagnostic accuracy of the Mood Disorder Questionnaire (MDQ) and McLean Screening Instrument for Borderline Personality Disorder (MSI) in a clinical inpatient setting and whether individual screening items could differentiate BD from BPD.Methods757 sequential inpatients admitted to a Mood Disorder Unit completed both the MDQ and MSI. Screen positive for the MDQ was defined as ≥7/13 symptoms endorsed with concurrence and at least moderate impact. Screen positive for the MSI was defined as a score of ≥7. The clinical discharge summary diagnosis completed by a board‐certified psychiatrist was used as the reference standard to identify concordance rates of a positive screen with clinical diagnosis. Individual items predicting one disorder and simultaneously predicting absence of other disorder by odds ratio (OR>and <1) were identified.ResultsBoth screening instruments were more specific than sensitive (MDQ 83.7%/ 67.8%, MSI 73.2% / 63.3%). MDQ individual items (elevated mood, grandiosity, increased energy, pressured speech, decreased need for sleep, hyperactivity) were significant predictors of BD diagnosis and non‐predictors of BPD diagnosis. Whereas MSI subitem, self‐harm behaviors/suicidal attempts predicted BPD in the absence of BD; distrust and irritability were additional predictors of BPD.ConclusionWhile this study is limited by the lack of structured diagnostic interview, these data provide differential symptoms to discriminate BD and BPD. Further work with larger datasets and more rigorous bioinformatics machine learning methodology is encouraged to continue to identify distinguishing features of these two disorders to guide diagnostic precision and subsequent treatment recommendations.
SARS-CoV-2 Related Ischemic Colitis in an Adolescent With Trisomy 21: Diagnostic Pitfalls and Considerations
Ma, Yiming , Deutsch, Gail , Tassel, Dane Van , Shub, Mitchell , Schroeder, Shauna , Krauss, Jennifer L., Davenport, Katherine P., Carpentieri, David , Carpentieri, David , Ma, Y

Mayo Clinic

Pediatric and Developmental Pathology | May 28, 2021 | Volume: 24 | Issue: 5 | Pages: 445-449

10.1177/10935266211015666 | PMID 34048305 Get It

Millions of patients seek medical attention for diarrhea, vomiting, nausea, and abdominal pain. In the current environment, it is important to recognize that these symptoms may be the only manifestation or may precede more serious systemic complications of COVID-19. Herein, we describe the first case of ischemic colitis (IC) in a young adult who presented with diarrhea and highlight the laboratory pitfalls for patients with COVID-19 presenting with gastrointestinal (GI) symptoms.
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma
Marin, Bianca M. , Porath, Kendra A. , Conage‐Pough, Jason E. , Oh, Ju‐Hee , Miller, Caitlyn L. , Kitange, Gaspar J. , Tian, Shulan , Mladek, Ann C. , Decker, Paul A. , McMinn, Madison H. , Stopka, Sylwia A. , Carlson, Brett L. , Burns, Terence, Agar, Nathalie Y.R. , Eckel‐Passow, Jeanette E. , Cochran, Jennifer R. , Elmquist, William F. , Marin, Bianca-Maria, Burgenske, Danielle M. , Gupta, Shiv K. , Bakken, Katrina, Burns, Terence C, Agar, Nathalie Y R , Marin, Bianca M , Stopka, Sylwia A , Mladek, Ann C , Jain, Sonia , Kim, Minjee , Talele, Surabhi , Decker, Paul A. , Regan, Michael S. , He, Lihong , Bakken, Katrina K. , Parney, Ian F. , Giannini, Caterina , Vaubel, Rachael A. , White, Forest M. , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | May 27, 2021 | Volume: 23 | Issue: 12 | Pages: 2042-2053

10.1093/neuonc/noab133 | PMID 34050676 Get It

Abstract Background Antibody drug conjugates (ADCs) targeting the epidermal growth factor receptor (EGFR), such as depatuxizumab mafodotin (Depatux-M), is a promising therapeutic strategy for glioblastoma (GBM) but recent clinical trials did not demonstrate a survival benefit. Understanding the mechanisms of failure for this promising strategy is critically important. Methods PDX models were employed to study efficacy of systemic vs intracranial delivery of Depatux-M. Immunofluorescence and MALDI-MSI were performed to detect drug levels in the brain. EGFR levels and compensatory pathways were studied using quantitative flow cytometry, Western blots, RNAseq, FISH, and phosphoproteomics. Results Systemic delivery of Depatux-M was highly effective in nine of 10 EGFR-amplified heterotopic PDXs with survival extending beyond one year in eight PDXs. Acquired resistance in two PDXs (GBM12 and GBM46) was driven by suppression of EGFR expression or emergence of a novel short-variant of EGFR lacking the epitope for the Depatux-M antibody. In contrast to the profound benefit observed in heterotopic tumors, only two of seven intrinsically sensitive PDXs were responsive to Depatux-M as intracranial tumors. Poor efficacy in orthotopic PDXs was associated with limited and heterogeneous distribution of Depatux-M into tumor tissues, and artificial disruption of the BBB or bypass of the BBB by direct intracranial injection of Depatux-M into orthotopic tumors markedly enhanced the efficacy of drug treatment. Conclusions Despite profound intrinsic sensitivity to Depatux-M, limited drug delivery into brain tumor may have been a key contributor to lack of efficacy in recently failed clinical trials.
TSPEAR variants are primarily associated with ectodermal dysplasia and tooth agenesis but not hearing loss: A novel cohort study
Bowles, Bradley , Ferrer, Alejandro , Nishimura, Carla, Rey, Tristan, Leheup, Bruno, Sullivan, Jennifer A. , Schoch, Kelly, Stong, Nicholas , Agolini, Emanuele , Cocciadiferro, Dario , Williams, Abigail , Cummings, Alex, Genovese, Silvia , Roadhouse, Chelsea, Network, Undiagnosed Diseases, Wentzensen, Ingrid M. , Li, Chumei , Babovic‐Vuksanovic, Dusica , Lanpher, Brendan C. , Dentici, Maria Lisa , Hamm, J. Austin, Shashi, Vandana , Gérard, Bénédicte , Bloch‐Zupan, Agnès , Smith, Richard J. , Klee, Eric W. , Oglesbee, Devin , McCauley, Jacob L. , Nelson, Stanley F. , Azamian, Mahshid S. , Martínez-Agosto, Julián A. , Chang, Ta Chen , Blue, Elizabeth , Woods, Jeremy D. , Baldridge, Dustin , Pinto E Vairo, Filippo, Sullivan, Jennifer , Agolini, Emanuele , Loddo, Sara , Genovese, Silvia , Li, Chumei , Babovic-Vuksanovic, Dusica, Dentici, Maria Lisa , Ankala, Arun , Radio, Francesca Clementina , Bloch-Zupan, Agnes , Oglesbee, Devin , Baldridge, Dustin , Stong, Nicholas , Ferrer, Alejandro , McCauley, Jacob L , Vairo, Filippo Pinto e , McWalter, Kirsty , Network, Undiagnosed Diseases, Dallapiccola, Bruno , Radio, Francesca Clementina

Mayo Clinic

American Journal of Medical Genetics Part A | May 27, 2021 | Volume: 185 | Issue: 8 | Pages: 2417-2433

10.1002/ajmg.a.62347 | PMID 34042254 Get It

AbstractBiallelic loss‐of‐function variants in the thrombospondin‐type laminin G domain and epilepsy‐associated repeats (TSPEAR) gene have recently been associated with ectodermal dysplasia and hearing loss. The first reports describing a TSPEAR disease association identified this gene is a cause of nonsyndromic hearing loss, but subsequent reports involving additional affected families have questioned this evidence and suggested a stronger association with ectodermal dysplasia. To clarify genotype–phenotype associations for TSPEAR variants, we characterized 13 individuals with biallelic TSPEAR variants. Individuals underwent either exome sequencing or panel‐based genetic testing. Nearly all of these newly reported individuals (11/13) have phenotypes that include tooth agenesis or ectodermal dysplasia, while three newly reported individuals have hearing loss. Of the individuals displaying hearing loss, all have additional variants in other hearing‐loss‐associated genes, specifically TMPRSS3, GJB2, and GJB6, that present competing candidates for their hearing loss phenotype. When presented alongside previous reports, the overall evidence supports the association of TSPEAR variants with ectodermal dysplasia and tooth agenesis features but creates significant doubt as to whether TSPEAR variants are a monogenic cause of hearing loss. Further functional evidence is needed to evaluate this phenotypic association.
Cognitive Impairment and Dementia After Stroke: Design and Rationale for the DISCOVERY Study
Rost, Natalia S. , Meschia, James F. , Wruck, Lisa , Helmer, Karl G. , Greenberg, Steven M. , Investigators*, on behalf of the DISCOVERY, Barrett, Kevin M. , Biffi, Alessandro , Fornage, Myriam , Etherton, Mark R. , Golland, Polina , Graff-Radford, Jonathan, Jack, Cliff R, Kalpathy–Cramer, Jayashree , Kittner, Steven J. , Lowe, Val J. , Petersen, Ronald C. , Sherman, Alexander , Viswanathan, Anand , Meschia, James F , Wruck, Lisa M , Gottesman, Rebecca F. , Investigators*, on behalf of the DISCOVERY, Boden-Albala, Bernadette M , Graff‐Radford, Jonathan , Hinman, Jason D. , Knopman, David S. , Manly, Jennifer J. , Mosley, Thomas H. , Rissman, Robert A. , Schirmer, Markus D. , Schwab, Kristin , Seshadri, Sudha , Sherman, Alexander, Vemuri, Prashanthi

Mayo Clinic

Stroke | May 27, 2021 | Volume: 52 | Issue: 8 | Pages: No page available

10.1161/strokeaha.120.031611 | PMID 34039035 Get It

Stroke is a leading cause of the adult disability epidemic in the United States, with a major contribution from poststroke cognitive impairment and dementia (PSCID), the rates of which are disproportionally high among the health disparity populations. Despite the PSCID’s overwhelming impact on public health, a knowledge gap exists with regard to the complex interaction between the acute stroke event and highly prevalent preexisting brain pathology related to cerebrovascular and Alzheimer disease or related dementia. Understanding the factors that modulate PSCID risk in relation to index stroke event is critically important for developing personalized prognostication of PSCID, targeted interventions to prevent it, and for informing future clinical trial design. The DISCOVERY study (Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on Recovery), a collaborative network of thirty clinical performance clinical sites with access to acute stroke populations and the expertise and capacity for systematic assessment of PSCID will address this critical challenge. DISCOVERY is a prospective, multicenter, observational, nested-cohort study of 8000 nondemented ischemic and hemorrhagic stroke patients enrolled at the time of index stroke and followed for a minimum of 2 years, with serial cognitive evaluations and assessments of functional outcome, with subsets undergoing research magnetic resonance imaging and positron emission tomography and comprehensive genetic/genomic and fluid biomarker testing. The overall scientific objective of this study is to elucidate mechanisms of brain resilience and susceptibility to PSCID in diverse US populations based on complex interplay between life-course exposure to multiple vascular risk factors, preexisting burden of microvascular and neurodegenerative pathology, the effect of strategic acute stroke lesions, and the mediating effect of genomic and epigenomic variation.
CSNK2B: A broad spectrum of neurodevelopmental disability and epilepsy severity
Ernst, Michelle, Baugh, Evan H., Thomas‐Wilson, Amanda , Bier, Louise , Lippa, Natalie , Stong, Nicholas , Mulhern, Maureen , Kushary, Sulagna , Akman, Cigdem I. , Heinzen, Erin L. , Yeh, Raymond, He, Weimin , Hanchard, Neil A. , Burrage, Lindsay C. , Leduc, Magalie S. , Chong, Josephine S. C., Bend, Renee, Lyons, Michael J. , Lee, Jennifer A. , Suwannarat, Pim, Brilstra, Eva H. , Simon, Marleen, Binsbergen, Ellen van , Groepper, Daniel , Fleischer, Julie , Keren, Boris , Mignot, Cyril , Mathieu, Sophie , Mancini, Grazia M.S. , Madan‐Khetarpal, Suneeta, Infante, Elena , Bluvstein, Judith , Seeley, Andrea , Bachman, Kristine , Klee, Eric W. , Schultz‐Rogers, Laura , Hasadsri, Linda , Barnett, Sarah , Ellingson, Marissa S. , Ferber, Matthew J. , Ramsey, Keri , Rauch, Anita , Joset, Pascal , Steindl, Katharina , Sheehan, Theodore , Vasquez, Alejandra , Ruivenkamp, Claudia , White, Susan M. , Monaghan, Kristin G. , Goldstein, David B. , Sands, Tristan T. , Aggarwal, Vimla S. , Ernst, Michelle E , Schultz-Rogers, Laura E, Sheehan, Theodore , Poduri, Annapurna , Sands, Tristan T , Rauch, Anita , Burrage, Lindsay C , Stong, Nicholas , Yeh, Raymond, Koopmans, Marion , Nava, Caroline , Narayanan, Vinodh , Pais, Lynn

Mayo Clinic

Epilepsia | May 27, 2021 | Volume: 62 | Issue: 7 | Pages: No page available

10.1111/epi.16931 | PMID 34041744 Get It

AbstractCSNK2B has recently been implicated as a disease gene for neurodevelopmental disability (NDD) and epilepsy. Information about developmental outcomes has been limited by the young age and short follow‐up for many of the previously reported cases, and further delineation of the spectrum of associated phenotypes is needed. We present 25 new patients with variants in CSNK2B and refine the associated NDD and epilepsy phenotypes. CSNK2B variants were identified by research or clinical exome sequencing, and investigators from different centers were connected via GeneMatcher. Most individuals had developmental delay and generalized epilepsy with onset in the first 2 years. However, we found a broad spectrum of phenotypic severity, ranging from early normal development with pharmacoresponsive seizures to profound intellectual disability with intractable epilepsy and recurrent refractory status epilepticus. These findings suggest that CSNK2B should be considered in the diagnostic evaluation of patients with a broad range of NDD with treatable or intractable seizures.
Recommendations for Statistical Reporting in Cardiovascular Medicine: A Special Report From the American Heart Association
Althouse, Andrew D. , Below, Jennifer E , Claggett, Brian , Cox, Nancy J. , Lemos, James A. de , Deo, Rahul C. , Duval, Sue , Hachamovitch, Rory , Kaul, Sanjay , Keith, Scott W. , Teixeira‐Pinto, Armando , Roger, Véronique L. , Below, Jennifer E , Secemsky, Eric A.

Mayo Clinic

Circulation | May 25, 2021 | Volume: 144 | Issue: 4 | Pages: No page available

10.1161/circulationaha.121.055393 | PMID 34032474 Get It

Statistical analyses are a crucial component of the biomedical research process and are necessary to draw inferences from biomedical research data. The application of sound statistical methodology is a prerequisite for publication in the American Heart Association (AHA) journal portfolio. The objective of this document is to summarize key aspects of statistical reporting that might be most relevant to the authors, reviewers, and readership of AHA journals. The AHA Scientific Publication Committee convened a task force to inventory existing statistical standards for publication in biomedical journals and to identify approaches suitable for the AHA journal portfolio. The experts on the task force were selected by the AHA Scientific Publication Committee, who identified 12 key topics that serve as the section headers for this document. For each topic, the members of the writing group identified relevant references and evaluated them as a resource to make the standards summarized herein. Each section was independently reviewed by an expert reviewer who was not part of the task force. Expert reviewers were also permitted to comment on other sections if they chose. Differences of opinion were adjudicated by consensus. The standards presented in this report are intended to serve as a guide for high-quality reporting of statistical analyses methods and results.
Neurodegeneration of the visual word form area in a patient with word form alexia
Chandregowda, Adithya , Lowe, Val J. , Whitwell, Jennifer L. , Josephs, Keith A. , Duffy, Joseph R. , Machulda, Mary M.

Mayo Clinic

Neurology and Clinical Neuroscience | May 24, 2021 | Volume: 9 | Issue: 4 | Pages: 359-360

10.1111/ncn3.12516 | PMID 34373787 Get It

Bro1 stimulates Vps4 to promote intralumenal vesicle formation during multivesicular body biogenesis
Tseng, Chun‐Che , Dean, Shirley, Davies, Brian A., Azmi, Ishara F. , Pashkova, Natalya , Payne, Johanna A., Staffenhagen, Jennifer, West, Matt , Piper, Robert C. , Katzmann, David J. , Katzmann, David J , Piper, Robert C , Dean, Shirley, Odorizzi, Greg

Mayo Clinic

Journal of Cell Biology | May 24, 2021 | Volume: 220 | Issue: 8 | Pages: No page available

10.1083/jcb.202102070 | PMID 34160559 Get It

Endosomal sorting complexes required for transport (ESCRT-0, -I, -II, -III) execute cargo sorting and intralumenal vesicle (ILV) formation during conversion of endosomes to multivesicular bodies (MVBs). The AAA-ATPase Vps4 regulates the ESCRT-III polymer to facilitate membrane remodeling and ILV scission during MVB biogenesis. Here, we show that the conserved V domain of ESCRT-associated protein Bro1 (the yeast homologue of mammalian proteins ALIX and HD-PTP) directly stimulates Vps4. This activity is required for MVB cargo sorting. Furthermore, the Bro1 V domain alone supports Vps4/ESCRT–driven ILV formation in vivo without efficient MVB cargo sorting. These results reveal a novel activity of the V domains of Bro1 homologues in licensing ESCRT-III–dependent ILV formation and suggest a role in coordinating cargo sorting with membrane remodeling during MVB sorting. Moreover, ubiquitin binding enhances V domain stimulation of Vps4 to promote ILV formation via the Bro1–Vps4–ESCRT-III axis, uncovering a novel role for ubiquitin during MVB biogenesis in addition to facilitating cargo recognition.
Development of a Competency Model for Placement and Verification of Nasogastric and Nasoenteric Feeding Tubes for Adult Hospitalized Patients
Powers, Jan , Brown, Britta , Lyman, Beth, Escuro, Arlene A. , Linford, Lorraine, Gorsuch, Kim, Mogensen, Kris M. , Engelbrecht, Jessica, Chaney, Amanda , McGinnis, Carol , Quatrara, Beth , Leonard, Jennifer , Guenter, Peggi , Mogensen, Kris M , Escuro, Arlene , Engelbrecht, Jessica

Mayo Clinic

Nutrition in Clinical Practice | May 22, 2021 | Volume: 36 | Issue: 3 | Pages: 517-533

10.1002/ncp.10671 | PMID 34021623 Get It

AbstractNasogastric/nasoenteric (NG/NE) feeding tube placements are associated with adverse events and, without proper training, can lead to devastating and significant patient harm related to misplacement. Safe feeding tube placement practices and verification are critical. There are many procedures and techniques for placement and verification; this paper provides an overview and update of techniques to guide practitioners in making clinical decisions. Regardless of placement technique and verification practices employed, it is essential that training and competency are maintained and documented for all clinicians placing NG/NE feeding tubes. This paper has been approved by the American Society for Parenteral and Enteral Nutrition (ASPEN) Board of Directors.